Today we’re announcing our Q3 2026 financial results and providing corporate updates.
Join us for a conference call and webcast at 8:30AM ET.
Call details:
- Conference Dial-In: 1-877-407-0792
- International Dial-In: 1-201-689-8263
- Conference ID: 13763324
- Webcast Link: viavid.webcasts.com/starther…
Learn more: investors.milestonepharma.co…
1
43
A breakthrough worth celebrating!
CARDAMYST® (etripamil) Nasal Spray has been named Cardiovascular BioPharma Innovation of the Year by the @BioTech_Awards .
This recognition belongs to the people whose dedication brought CARDAMYST to life. Thank you to our team, clinical partners, and most importantly, the patients who inspire our work to improve the lives of people living with cardiac conditions.
#BioTechBreakthrough #PSVT #SVT #Cardiology #BioPharma
60
Last week, Milestone Pharma joined leaders from across the life sciences community for the 20th anniversary of the Galien Foundation USA Awards.
Congratulations to @Novartis, recipient of the 2026 Best Pharmaceutical Product award, and to all this year’s category winners and honorees. The evening celebrated the remarkable scientific advancements shaping the future of medicine and improving patients’ lives.
We were proud to see CARDAMYST® (etripamil) Nasal Spray recognized among this year’s nominees and to share the occasion with so many dedicated healthcare innovators.
#PrixGalien #Pharma
60
NEWS UPDATE!
Today we announced we will be presenting at the @American Heart Association #ScientificSessions26.
Learn more in the press release: investors.milestonepharma.co…
#SVT #PSVT #Cardiology #AHA26
56
We were thrilled to team up with CBS Mornings recently to help raise awareness of PSVT and CARDAMYST® (etripamil). See the feature here: youtube.com/watch?v=NjjxtFai…
Indication
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)
What is CARDAMYST?
CARDAMYST is a prescription medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).
It is not known if CARDAMYST is safe and effective in children.
Do not use CARDAMYST if you:
are allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete list of ingredients in CARDAMYST.
have limitations in activities due to heart failure (moderate to severe heart failure).
have Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).
have sick sinus syndrome without a permanent pacemaker.
have second degree or higher atrioventricular (AV) block.
Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:
have a history of fainting.
have low blood pressure.
are pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this time, pump and throw away your breast milk. Talk to your healthcare provider about the best way to feed your baby after using CARDAMYST.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of CARDAMYST?
CARDAMYST may cause serious side effects, including:
Fainting due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart. CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting and certain heart problems, or people with a history of fainting during an episode of PSVT. Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting occurs after using CARDAMYST, caregivers should place you on your back and seek medical help.
The most common side effects of CARDAMYST include nasal discomfort, nasal congestion, runny nose, throat irritation, nosebleeds.
These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see the full Prescribing Information
milestonepharma.com/etripami… for CARDAMYST.
169
BREAKING NEWS!
We have an exciting lineup of data presentations starting this week:
@CardioApp – October 22, 2026
@crfheart (TCT) – November 2, 2026
@AHAScience – November 7, 2026
Details can be found here: investors.milestonepharma.co…
106
Milestone has been honored with TWO Pinnacle Awards for Human Resources: Best Place to Work by Company Size/Region - Diamond 🏆 and Onboarding & New Hire Experience – Platinum 🏆.
Thank you to every Milestone colleague who brings our culture to life.
Learn more: einnews.com/pr_news/94906379…
42
The burden of supraventricular tachycardia (#SVT), also called #PSVT, can extend beyond the episode itself.
Watch below to hear our President & CEO, Joe Oliveto explain why understanding the patient experience is essential when considering the need for new treatment options.
@Stocktwits
#Cardiology
1
51
NEWS UPDATE!
We are excited to announce the Dutch Cardiovascular Investigator Network (WCN) has enrolled their first participant in the ReVeRA-301 Phase 3 pivotal trial. WCN was recently activated as the first EU site in this global study.
Learn more: investors.milestonepharma.co…
52
Check out this recent conversation with @Stocktwits and our President and CEO, Joe Oliveto to learn more about where Milestone is at as a company today and what important work in #cardiology is on the horizon.
#MIST #SVT #AFib
42
Thank you to @InsideEdition for connecting with cardiologist Dr. Stephanie Saucier about paroxysmal supraventricular tachycardia (#PSVT), commonly called #SVT.
Dr. Saucier shared an important update on a first-of-its kind treatment approach.
Check out the segment here: youtube.com/watch?v=GoQBfdKH…
35
NEWS UPDATE!
We are excited to announce that the Montreal Heart Institute has enrolled their first participant in the ReVeRA-301 Phase 3 pivotal trial. The Institute was recently activated as the first Canadian site in this global study.
Learn more in the press release: investors.milestonepharma.co…
#Cardiology #AFib #EPeeps
We were proud to be part of #HRXLive, an event powered by the @HRSonline.
Thank you to the clinicians, researchers, engineers, investors and innovators who shared their perspectives and helped make this year’s event such an engaging experience!
#HRX2026 #EPeeps
20
We’re looking forward to joining Cantor Fitzgerald at their upcoming Global Healthcare Conference.
Discover more about our work to advance innovative cardiovascular medicines: investors.milestonepharma.co…
#MIST #InvestorRelations #IR
1
20
Our President and CEO, Joe Oliveto will participate in a fireside chat today at the @Wells Fargo21st Annual #Healthcare Conference.
Webcast link: event.summitcast.com/view/aM…
#MIST #Biotech #Cardiology #Investing
18
NEWS UPDATE! China’s National Medical Products Administration (NMPA) has approved etripamil for adults with paroxysmal supraventricular tachycardia (#PSVT) in China.
Learn more in the press release: investors.milestonepharma.co…
15
September will be an exciting month for Milestone Pharmaceuticals!
We look forward to engaging with our investor community at upcoming conferences, sharing our recent progress in the cardiovascular space and discussing the opportunities ahead.
Learn more here: investors.milestonepharma.co…
#InvestorRelations #Cardiology
10
Today we announced findings from a longitudinal survey study describing how paroxysmal supraventricular tachycardia (#PSVT) affects patients’ daily lives and quality of life in the periods between episodes.
Learn more: investors.milestonepharma.co…
Thank you Dr. Sean Pokorney and @DCRINews for your contributions to this important field of research!
#ESCCongress
11












